Lymphoma (includes NHL, HL, CNS Lymphoma)
Featured Articles
(Merck) July 9, 2019 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLAs) to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include an every-six-weeks (Q6W)...
Read Article
(San Francisco Business Times) June 19, 2019 - A small San Francisco drug company offering a new protein-degrading approach to fight blood cancers and other diseases cut a potential $2.3 billion deal with giant Gilead Sciences Inc. to discover drugs that Gilead then could license. In the multi-year deal, Foster City-based Gilead will...
Read Article
Latest Articles
July 16, 2019
July 15, 2019
July 11, 2019
July 09, 2019
July 09, 2019
July 02, 2019
July 01, 2019
June 25, 2019
View More
News Commentary
Editor Image
11 Feb, 2019 | by William McGivney, PhD
Breast Implants; Déjà Vu All Over Again Last week’s FDA warning...
View Comment
Editor Image
16 Nov, 2018 | by
It seems too early to approve this drug.
View Comment
View More
OBR Green
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.
OBR Blog
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018
By Lynne Lederman, PhD As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two... Read more
December 03, 2018